Your browser doesn't support javascript.
loading
CD28 costimulation augments CAR signaling in NK cells via the LCK/CD3Z/ZAP70 signaling axis.
Acharya, Sunil; Basar, Rafet; Daher, May; Rafei, Hind; Li, Ping; Uprety, Nadima; Ensley, Emily; Shanley, Mayra; Kumar, Bijender; Banerjee, Pinaki P; Melo Garcia, Luciana; Lin, Paul; Mohanty, Vakul; Kim, Kun Hee; Jiang, Xianli; Pan, Yuchen; Li, Ye; Liu, Bin; Nunez Cortes, Ana Karen; Zhang, Chenyu; Fathi, Mohsen; Rezvan, Ali; Montalvo, Melisa J; Cha, Sophia L; Reyes-Silva, Francia; Shrestha, Rejeena; Guo, Xingliang; Kundu, Kiran; Biederstadt, Alexander; Muniz-Feliciano, Luis; Deyter, Gary M; Kaplan, Mecit; Jiang, Xin Ru; Liu, Enli; Jain, Antrix; Roszik, Janos; Fowlkes, Natalie W; Solis Soto, Luisa M; Raso, Maria Gabriela; Khoury, Joseph D; Lin, Pei; Vega, Francisco; Varadarajan, Navin; Chen, Ken; Marin, David; Shpall, Elizabeth J; Rezvani, Katayoun.
  • Acharya S; The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
  • Basar R; The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
  • Daher M; The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
  • Rafei H; The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
  • Li P; The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
  • Uprety N; The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
  • Ensley E; The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
  • Shanley M; The University of Texas MD Anderson Cancer Center, Houston, United States.
  • Kumar B; The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
  • Banerjee PP; Baylor College of Medicine, Houston, Texas, United States.
  • Melo Garcia L; The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
  • Lin P; The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
  • Mohanty V; The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
  • Kim KH; The University of Texas MD Anderson Cancer Center, Houston, Texas, United States.
  • Jiang X; The University of Texas MD Anderson Cancer Center, United States.
  • Pan Y; The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
  • Li Y; The University of Texas MD Anderson Cancer Center, Houston, United States.
  • Liu B; The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
  • Nunez Cortes AK; The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
  • Zhang C; The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
  • Fathi M; CellChorus, Houston, United States.
  • Rezvan A; University of Houston, Houston, Texas, United States.
  • Montalvo MJ; University of Houston, Houston, TX, United States.
  • Cha SL; The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
  • Reyes-Silva F; The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
  • Shrestha R; The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
  • Guo X; The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
  • Kundu K; The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
  • Biederstadt A; The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
  • Muniz-Feliciano L; The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
  • Deyter GM; The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
  • Kaplan M; The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
  • Jiang XR; The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
  • Liu E; The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
  • Jain A; Baylor College of Medicine, HOUSTON, United States.
  • Roszik J; The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
  • Fowlkes NW; The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
  • Solis Soto LM; The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
  • Raso MG; The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
  • Khoury JD; University of Nebraska Medical Center, Omaha, United States.
  • Lin P; The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
  • Vega F; The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
  • Varadarajan N; University of Houston, Houston, Texas, United States.
  • Chen K; The University of Texas MD Anderson Cancer Center, Houston, Texas, United States.
  • Marin D; The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
  • Shpall EJ; The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
  • Rezvani K; The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Cancer Discov ; 2024 Jun 20.
Article en En | MEDLINE | ID: mdl-38900051
ABSTRACT
Multiple factors in the design of a chimeric antigen receptor (CAR) influence CAR T-cell activity, with costimulatory signals being a key component. Yet, the impact of costimulatory domains on the downstream signaling and subsequent functionality of CAR-engineered natural killer (NK) cells remains largely unexplored. Here, we evaluated the impact of various costimulatory domains on CAR-NK cell activity, using a CD70-targeting CAR. We found that CD28, a costimulatory molecule not inherently present in mature NK cells, significantly enhanced the antitumor efficacy and long-term cytotoxicity of CAR-NK cells both in vitro and in multiple xenograft models of hematologic and solid tumors. Mechanistically, we showed that CD28 linked to CD3Z creates a platform that recruits critical kinases, such as LCK and ZAP70, initiating a signaling cascade that enhances CAR-NK cell function. Our study provides insights into how CD28 costimulation enhances CAR-NK cell function and supports its incorporation in NK-based CARs for cancer immunotherapy.

Texto completo: 1 Banco de datos: MEDLINE Idioma: En Año: 2024 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Idioma: En Año: 2024 Tipo del documento: Article